Johnson & Johnson (JNJ) is seeing good growth from its Medical Technology division as people are opting for elective procedures again.

Johnson & Johnson (JNJ) is set to spin off its Consumer Brands division this week, which could make J&J a faster growing company.

Johnson & Johnson (JNJ) delivered solid profit growth of 10% last qtr even though sales fell because of the strong US dollar.

Currency exchange is expected to cut Johnson & Johnson’s (JNJ) profits (EPS) from $10.73 to $10.05 this year. Strong US dollar.

The combination of inflation and a strong US dollar hurt Johnson & Johnson’s (JNJ) profits last qtr and reduced estimates for the year.

Johnson & Johnson (JNJ) begins to see the benefits of increased demand for general and advanced surgery post-Covid.

Johnson & Johnson (JNJ) is planning to split into two companies, which might end up making JNJ stock grow faster than it has.

Analysts have high expectations for Johnson & Johnson (JNJ), as the estimated growth rate has been accelerating lately.

Johnson & Johnson (JNJ) is growing profits at double-digit rates again. Our 2021 Fair Value in this $165 stock is $198.

Johnson & Johnson (JNJ) had revenue suffer due to people postponing elective surgeries. Now, things are looking up.

Johnson & Johnson (JNJ) stock has nice upside potential, even if its (potential) COVID-19 vaccine delivers profits.

Johnson & Johnson (JNJ) has a pipeline of new drugs including a nasal spray for depression and COVID-19 vaccine candidate.

J&J (JNJ) is optimistic it can have a COVID-19 vaccine by early 2021. But slow medical device sales are hurting profits now.

Johnson & Johnson (JNJ) was overcome by legislation fears last year. But now the stock is back to All-Time highs.

Johnson & Johnson (JNJ) is in the news for is in the news for opioid and talcum powder, I see this as a buying opportunity.

Johnson & Johnson (JNJ) is in the news due to talcum powder and opioid litigation, and this seems to be holding JNJ down.

The state of Oklahoma is suing Johnson & Johnson (JNJ) for fueling the opioid epidemic. JNJ declined last week as trails began.

Johnson & Johnson (JNJ) lowered 2019 profit estimates after it reported earnings. But estimates of 5% growth at J&J are par for the course for this 6-7% grower.

John & Johnson (JNJ) is one of the safest stocks in the world, while growing 6% and paying a 3% yield. Now JNJ’s growing faster.

Johnson & Johnson (JNJ) had profit growth of 15% last qtr on 11% sales growth. Both figures are impressive. With the stock still down on the year, it’s a good time to buy.

Johnson & Jonson (JNJ) offers growth, a fat dividend, and a discount. This quality name is well worth the 15x earnings its selling for.

Johnson & Johnson (JNJ) is more than 10% off its highs. And with profits growing strong, I feel this is a great time to get mom and pop aboard the J&J train.

Johnson & Johnson (JNJ) just took sales growth and profit growth to another level — the double digit level. And with a P/E of 18 the stock is quite reasonable.

Johnson & Johnson (JNJ) has delivered 6% annual profit growth on average the past decade. Now with the U.S. dollar weakening, JNJ might grow profis 10%.

Johnson & Johnson (JNJ) has grown profits 6% per year the past decade, but its possible the company could grow profits 9% for the third year in a row.

Johnson & Johnson (JNJ) is one of THE safest stocks in the world, but investors shouldn’t expect double-digit growth from this high quality company.

Johnson & Johnson (JNJ) is having an outstanding year, and also has up to 10 Billion dollar drugs in its pipeline to boost future profits.

Johnson & Johnson (JNJ) is up 20% this year and growth looks good for the remainder of 2016.

Johnson & Johnson (JNJ) just put out a decent quarter and upped earnings estimates. Things are looking up for J&J.

I think Johnson & Johnson (JNJ) is the world’s safest stock, which is perfect with these volatile stock market conditions.